Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apricitabine vs lamivudine in treatment-experienced HIV-1 with M184V/I mutation
2007-003281-18Phase 3Active
- Sponsor
- Avexa Limited
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of apricitabine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Avexa Limited. Primary endpoint: Virologic response at Week 24. Started Jan 2008; status: active.
02
Drugs
apricitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2007-003281-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003281-18.